Several factors may explain the low efficacies observed so far, including toxicity, drug resistance, alternative mechanisms of angiogenesis, and the challenge of identifying the right patient who will benefit from anti-VEGF therapy in breast cancer. Here, VEGFA is linked to breast carcinoma.